© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
June 11th 2021, 1:00pm
Treatment with an investigational drug induced high response rates in patients with relapsed or refractory multiple myeloma.
June 8th 2021, 9:00pm
Patients with relapsed/refractory myeloma who were previously treated with three or more therapies responded to an infusion of a novel CAR-T cell therapy up to 18 months with no new side effects compared with 12-month results of this study.
June 8th 2021, 6:30pm
The study’s lead author noted that a survival outcome, along with other results, was similar among the two groups.
June 6th 2021, 8:00pm
After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.
June 5th 2021, 8:00pm
A single infusion of a novel CAR-T cell therapy was associated with early and deep responses to treatment among a certain group of patients with multiple myeloma.
June 2nd 2021, 4:09pm
Donna and Dr Gasparetto close the discussion by highlighting the importance of physicians utilizing their patients, as well as patients being involved with their multiple myeloma treatment.
June 2nd 2021, 4:03pm
Donna gives advice to other multiple myeloma patients about what she has learned from living with this disease and her various therapies.
May 26th 2021, 1:00pm
Researchers have developed Myeloma Drug Sensitivity Testing to determine which medications will be most effective with minimal side-effects.
May 21st 2021, 1:45pm
Cristina Gasparetto, MD, discusses Donna’s relationship with the drug carfilzomib for multiple myeloma therapy, as well as her second relapse.
Donna and Dr Gasparetto converse about the many first- and second-line therapies for multiple myeloma.
A Milkshake and Metastatic Cancer
Fighting Hard for Patients with Fibrolamellar Carcinoma
Masking in a ‘Post-Pandemic’ World
A Guardian Angel Among Doctors